INVO Fertility (IVF) Planet MicroCap Las Vegas 2026 summary

Business overview and strategy

• Focuses on fertility industry, offering INVOcell device as an alternative to conventional IVF.

• Expanded from medical device development to operating four fertility clinics in the U.S.

• Pursues growth through acquisitions and organic strategies within existing clinics.

• Recently rebranded and obtained a new ticker symbol to align with core business.

• Strengthened operations team with experienced clinical professionals for next growth phase.

Financial and capital structure developments

• Simplified capital structure by retiring convertible preferred shares and eliminating warrant liabilities.

• Raised $11.5 million in gross proceeds through financings at the end of last year and January.

• Completed majority divestiture of unrelated business, focusing resources on fertility operations.

• Conducted a reverse stock split to maintain NASDAQ compliance.

• Fully diluted share count could reach 4.85 million, potentially adding $15 million in cash.

Market and industry trends

• U.S. fertility market estimated at $6 billion, with steady growth and increasing insurance coverage.

• About 60% of clinics consolidated under larger networks, but market remains fragmented.

• Private equity has driven much of the consolidation, but many owner-operated clinics remain.

• Demand driven by high infertility rates and improving affordability.

• Public policy is supporting further insurance coverage expansion.